<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625532</url>
  </required_header>
  <id_info>
    <org_study_id>BER-LUT-2015-02</org_study_id>
    <secondary_id>2015-003856-31</secondary_id>
    <nct_id>NCT02625532</nct_id>
  </id_info>
  <brief_title>Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles (LUTEAL Trial)</brief_title>
  <acronym>LUTEAL</acronym>
  <official_title>Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles: A Randomized Comparative Single Center Trial. LUTEAL Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Bernabeu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Bernabeu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory, prospective, randomized, comparative, open trial with control group treated to&#xD;
      assess the efficacy of follicular phase ovarian stimulation compared to lutheal phase ovarian&#xD;
      stimulation in women with Bologna criteria for poor ovarian response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two arms is established, the study group that will start ovarian stimulation in the luteal&#xD;
      phase and the control group that will start ovarian stimulation in the follicular phase.&#xD;
&#xD;
      The randomization will be made in the 2-3 day of the menstrual cycle, according to a list of&#xD;
      random allocation of treatments. After check that there is no contraindication to start the&#xD;
      stimulation, the patients will be assigned to the treatment group.&#xD;
&#xD;
      The patients in the control group (follicular phase group) will start stimulation with two&#xD;
      vials of 150 IU recombinant FSH + 75 IU recombinant LH (Pergoveris® 150/75). The patients in&#xD;
      the study group (luteal phase group) will perform daily urine LH test from day 7th of the&#xD;
      cycle and will start the administration of 150 IU recombinant FSH + 75 IU recombinant LH&#xD;
      (Pergoveris® 150/75) at two vials daily from the 4th day of the LH positive test.&#xD;
&#xD;
      Antagonist cetrorelix acetate (Cetrotide® ) administration will start when the largest&#xD;
      follicle shall be equal or greater than 14 mm. From this moment controls every 24-72 hours&#xD;
      with foliculometría by ultrasound and blood hormone analysis with determination of estradiol&#xD;
      and progesterone. For the final oocyte maturation 2 vials daily of 0.2 mg triptorelin acetate&#xD;
      (Decapeptyl®) is administered. Oocyte collection will be made by transvaginal&#xD;
      ultrasound-guided puncture according to IB protocol&#xD;
&#xD;
      The dosages and protocols used will be the usual for patients with diagnostic of poor ovarian&#xD;
      response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of oocytes in metaphase II obtained</measure>
    <time_frame>Through study completion, average 2 weeks</time_frame>
    <description>number of oocytes in metaphase II obtained by follicular puncture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of oocytes cumulus complexes</measure>
    <time_frame>Through study completion, average 2 weeks</time_frame>
    <description>number of oocytes cumulus complexes obtained by follicular puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of stimulation (days)</measure>
    <time_frame>Through study completion, average 2 weeks</time_frame>
    <description>number of days from the start of ovarian stimulation until the day of follicular puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cycle cancellation rate</measure>
    <time_frame>Through study completion, average 2 weeks</time_frame>
    <description>ratio of canceled cycles regarding the number of ovarian stimulation cycles initiated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing hormone levels following administration of agonist for final oocyte maturation</measure>
    <time_frame>Through study completion, average 2 weeks</time_frame>
    <description>Luteinizing hormone blood levels the day after administration of agonist for final oocyte maturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of side effects</measure>
    <time_frame>Through study completion, average 2 weeks</time_frame>
    <description>occurrence of side effects at the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fertilization rate</measure>
    <time_frame>Through study completion, average 2 weeks</time_frame>
    <description>Number of correct fertilization oocytes 18 hours post-insemination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Reproductive Techniques, Assisted</condition>
  <arm_group>
    <arm_group_label>Follicular phase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controlled ovarian stimulation starts during follicular phase on day 2-3 of the menstrual cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Luteal phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Controlled ovarian stimulation starts during luteal phase on day 3 to 5 after first LH positive urine test</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Follicular phase</intervention_name>
    <description>Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate</description>
    <arm_group_label>Follicular phase</arm_group_label>
    <other_name>Ovarian stimulation starts during the follicular phase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Luteal phase</intervention_name>
    <description>Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate</description>
    <arm_group_label>Luteal phase</arm_group_label>
    <other_name>Ovarian stimulation starts during the luteal phase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient Bologna meets the criteria to be diagnosed as low responder&#xD;
&#xD;
          -  Age under 41 years&#xD;
&#xD;
          -  Regular menstrual cycles between 21 and 35 days&#xD;
&#xD;
          -  Indication of in vitro fertilization&#xD;
&#xD;
          -  Indication of start stimulation with 300 IU of FSH&#xD;
&#xD;
          -  Presence of both ovaries&#xD;
&#xD;
          -  Ability to participate and comply with the study protocol&#xD;
&#xD;
          -  Having signed the written consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of follicles larger than 10 mm in the randomization visit&#xD;
&#xD;
          -  Endometriosis III / IV&#xD;
&#xD;
          -  Concomitant uterine pathology: adenomyosis, submucosal myomas, Asherman's syndrome...&#xD;
&#xD;
          -  Concurrent participation in another study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquín Llácer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Bernabeu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Bernabeu</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Bernabeu</investigator_affiliation>
    <investigator_full_name>Joaquín Llácer</investigator_full_name>
    <investigator_title>Gynaecologist. Reproductive Medicine Specialist at Instituto Bernabeu</investigator_title>
  </responsible_party>
  <keyword>Controlled Ovarian stimulation</keyword>
  <keyword>Follicular phase</keyword>
  <keyword>Luteal phase</keyword>
  <keyword>Reproductive Techniques, Assisted</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

